Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
5,053 total articles
Shannon L. Devers, Executive Vice President and Chief Human Resources Officer at Ionis Pharmaceuticals, completed a sale of nearly $323,500 worth of stock in late January 2026. The transaction occurred near the company’s 52-week high and precedes an anticipated earnings announcement. Meanwhile, Ionis continues progressing with recent regulatory app…
Chris Wren, Vice President of Operations at Planet 13 Holdings Inc, liquidated 30,000 company shares in late January 2026, amid the company's efforts to pivot its strategy following less-than-expected third-quarter earnings. Planet 13 reported $23.3 million in revenue and a negative EPS, prompting strategic exits including the California market to …
Amprius Technologies’ Chief Technology Officer, Stefan Constantin Ionel, recently sold over half a million shares totaling around $6.83 million while simultaneously exercising stock options. This activity unfolds during a period of significant stock appreciation and notable company initiatives including a new CEO transition and expanded production …
Michael F. MacLean, CFO of Avidity Biosciences Inc, executed a sale of 4,542 shares worth roughly $329,067 on January 21, 2026, in conformity with company equity incentive policies. The stock transaction occurred near its 52-week peak at $72.74 following a significant annual stock performance gain. In parallel, Avidity unveiled a Managed Access Pro…
Steven George Hughes, Chief Medical Officer at Avidity Biosciences, sold nearly 4,900 shares worth $354,642 to satisfy tax obligations related to recently vested Restricted Stock Units. This sale precedes multiple strategic developments at Avidity, including a new FDA-backed access program for its investigational muscular dystrophy therapy and an i…
W. Michael Flanagan, Chief Scientific Officer at Avidity Biosciences, recently sold 6,534 shares valued at approximately $473,388 to fulfill tax requirements related to restricted stock units. Meanwhile, Avidity is rolling out a Managed Access Program for its drug targeting Duchenne muscular dystrophy and has agreed to be acquired by Novartis in a …
On January 21, 2026, Avidity Biosciences’ President and CEO, Sarah Boyce, executed a sale of 14,387 shares in the company valued at approximately $1.04 million. The transaction, conducted near the stock's 52-week high, was performed to fulfill tax withholding on recently vested restricted stock units, as stipulated by the company's equity incentive…
On January 22, 2026, Comerica Executive Vice President James McGregor Carr completed a sale of 10,000 shares of company stock valued at roughly $980,600. This transaction occurred at prices close to the stock's annual peak and comes as Comerica pursues a merger with Fifth Third Bancorp, with recent earnings surpassing expectations.
William Radford Lovett II, a notable 10% shareholder of Dream Finders Homes, conducted a sizeable divestiture of Class A shares across two days in January 2026. These transactions unfolded while the company’s stock trades at a low price-to-earnings ratio, accompanied by a recent executive update on an expanded share repurchase plan and fresh market…
James Harry Weber, Executive Vice President of Comerica, executed significant stock sales and option exercises on January 22, 2026, coinciding with Comerica's robust stock performance and a pending merger. Despite Comerica's stock trading above its fair value and a high price-to-earnings ratio, the bank continues to demonstrate financial stability …
Rapid7's Chief Accounting Officer, Scott M. Murphy, has sold a portion of his holdings amid a significant year-over-year share price decline. The move comes ahead of an upcoming earnings report and follows mixed analyst opinions regarding the cybersecurity firm's growth prospects and valuation. Strategic initiatives including partnerships and produ…
On January 21, 2026, Argan Inc. Director Cynthia Flanders sold 19,000 shares of the company’s common stock, generating proceeds of approximately $7.35 million. Following this sale, Flanders remains a shareholder with a stake of 26,207 shares. Concurrently, Argan Inc. reported its fiscal third-quarter earnings, posting earnings per share surpassing …
Craig W. Kliethermes, CEO of RLI Corp, increased his ownership by acquiring 5,000 shares valued at $287,250 in late January 2026. This move comes alongside the company's recently announced fourth-quarter 2025 financial results, which showed earnings per share surpassing forecasts yet revenue falling short. Analysts present a range of perspectives o…
Gregory James Quarles, CEO Emeritus of Applied Energetics Inc., carried out a share sale along with exercising stock options on January 21, 2026. Concurrently, the company made notable strides by being selected for the Missile Defense Agency’s SHIELD program and adding Dr. Matthew Seaford to its Advisory Board, emphasizing growth in the defense and…
Yelp Inc.'s CEO Jeremy Stoppelman recently divested $2.59 million worth of company shares while simultaneously exercising stock options and maintaining a substantial personal stake. These moves took place amid shares trading close to their 52-week low, below analyst valuations, even as Yelp posted earnings surpassing expectations and pursued strate…
Brett Schulman, CEO and President of Cava Group Inc., sold 21,650 shares valued around $1.46 million to fulfill tax withholding obligations linked to vested restricted stock units. Despite fluctuations in stock price and varying analyst projections, the company maintains strong profitability and liquidity fundamentals while announcing a key executi…
Theodoros Xenohristos, Director and Chief Concept Officer of Cava Group, Inc., divested 965 shares on January 21, 2026, primarily to cover tax obligations. This sale comes during a period where Cava's stock has experienced declines over the past six months, although it remains above its 52-week low. Despite market volatility, the company maintains …
Novanta Inc.'s CEO, Matthijs Glastra, executed a significant stock sale in January 2026, disposing of 7,500 shares at $140 each, amounting to $1.05 million. This transaction occurred as the company's shares demonstrated considerable upward momentum despite trading below their 52-week peak. Concurrently, Novanta revised its earnings forecasts amid a…
On January 23, 2026, Alan H Kumler, serving as Senior Vice President and Chief Accounting Officer at United Community Banks, sold over twelve thousand shares of the bank's common stock valued at approximately $425,800. This transaction took place during a period when the company reported quarterly earnings in line with analyst estimates and surpass…
David R. Bickerton, a board member of Consumers Bancorp Inc, recently enhanced his investment in the company by purchasing 200 shares valued at $5,472. These acquisitions occurred in two transactions on January 23, 2026, at prices slightly above $27 per share. Consumers Bancorp's stock is trending near its highest level in the last year, reflecting…
Iridex Corporation's CFO Romeo R. Dizon recently increased his stake by purchasing 5,221 shares of company stock at an average price of $1.4779, amid a period of strong stock performance and promising preliminary financial results. Despite reporting negative earnings and recent net losses, Iridex shows signs of revenue growth and advancing treatmen…
Beam S Craig, a director at Peoples Bancorp Inc, increased his stake by purchasing 157 shares on January 23, 2026. This insider buying occurred while the bank reported slightly better-than-expected earnings per share but missed revenue projections for the fourth quarter of 2025. Despite these mixed results, Peoples Bancorp continues to offer an att…
On January 22, 2026, Suresh V. Garimella, a director at Modine Manufacturing Co, executed a sale of 1,100 common shares valued at $165,000 under a pre-arranged plan. This transaction occurs in the context of Modine Manufacturing's recent increase in its revolving credit facility and upcoming leadership changes in its Climate Solutions division, alo…
On January 21, 2026, Edgewise Therapeutics' director Badreddin Edris sold over 115,000 shares of the company's stock, raising approximately $3.39 million. This sale was conducted under an established Rule 10b5-1 plan. On the same day, Edris also exercised stock options, acquiring a similar number of shares at much lower prices. These insider activi…
On January 22, 2026, Serina Therapeutics’ Chief Scientific Officer, Randall Moreadith, disposed of 2,500 shares of common stock at $2.95 per share, totaling $7,375. This sale came despite the stock trading lower at $2.72 and a 46.47% decline over six months. Concurrently, Moreadith exercised options for 2,500 shares at a $0.06 exercise price. Serin…
